PEPTIDES
Pemvidutide Cut Heavy Drinking in a Small Trial. Now the FDA Is Next.
Pemvidutide, Altimmune's investigational once-weekly peptide, was developed primarily for serious liver diseases. Now it has produced a signal in a different condition: alcohol use...
PEPTIDES
Boehringer’s Obesity Triple Agonist Adds a Neuropeptide Y Receptor. Phase 2 Will Test the Bet
Most next-generation obesity peptides are variations on a familiar theme: combine GLP-1 with GIP, glucagon or another metabolic target, and see whether the result...
PEPTIDES
Novo Is Bringing Wegovy Pill Real-World Data to Obesity Week. Telehealth Patients Are the Sample
Novo Nordisk is bringing another round of real-world evidence on its Wegovy pill to ObesityWeek 2026, and much of it comes from an unusual...
PEPTIDES
Eccogene Wants an Amylin Agonist in Pill Form. Its First Data Are Still Preclinical
For most of the last three years, the amylin story in obesity medicine has been a peptide story. Novo Nordisk built cagrilintide, Zealand Pharma...
PEPTIDES
BPC-157 Got a Federal Compounding Pass Before Its First Placebo-Controlled Trial Finished
For a peptide promoted to athletes, wellness clinics and online buyers for years, BPC-157 has a remarkably thin record in humans.
That gap became more...
PEPTIDES
Kailera’s 5,000-Patient Phase 3 Program Is Full. Ribupatide’s Big Test Arrives in 2028.
Kailera Therapeutics has done one of the most expensive, unglamorous jobs in obesity drug development: it has filled its pivotal trials. In its November...
PEPTIDES
Avexitide Blocks the GLP-1 Receptor Instead of Boosting It. Amylyx Wants FDA Approval by Year End
Most of the obesity-drug business is built on turning the GLP-1 receptor up. Amylyx Pharmaceuticals is trying to win approval for a peptide that...
PEPTIDES
Viking Raised $575 Million and Filled Its Phase 3 Trials. VK2735’s Monthly Dosing Question Waits Until 2028
VK2735 has become one of the most closely watched obesity drugs that neither Eli Lilly nor Novo Nordisk owns. In its October 28 third-quarter...
